Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
Johnson & Johnson (NYSE:JNJ) reported preliminary Phase 1b results showing the bispecific T-cell engager pasritamig plus docetaxel produced deep, durable PSA reductions and a safety profile consistent with docetaxel alone. Among 51 patients, PSA declines ≥50% occurred in 64.7% overall and 75.0% of taxane-naïve patients. No cytokine release syndrome or treatment-related deaths were observed. The program is advancing into Phase 3 studies, with two trials ongoing and regulatory designations in China and the U.S.
Johnson & Johnson (NYSE: JNJ) submitted an sBLA to the FDA on Feb 24, 2026, seeking approval of IMAAVY (nipocalimab) as the first treatment for warm autoimmune hemolytic anemia (wAIHA).
Phase 2/3 ENERGY showed a rapid, durable hemoglobin response and improved fatigue versus placebo; IMAAVY was generally well tolerated. Full ENERGY results are forthcoming.
Johnson & Johnson (NYSE: JNJ) reported long-term QUASAR LTE results showing sustained TREMFYA (guselkumab) benefit through Week 140 in adults with moderately to severely active ulcerative colitis. At Week 140, 80.8% were in clinical remission, 78.6% achieved histo-endoscopic mucosal improvement, and 53.6% reached endoscopic remission.
About 89% of eligible participants completed treatment through Week 140, 87.5% of Week 44 remitters stayed in remission through Week 140, efficacy held regardless of prior biologic/JAK history, and no new safety concerns were observed.
Johnson & Johnson (NYSE:JNJ) reported Phase 1b/2 OrigAMI-4 results showing first-line subcutaneous RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) plus pembrolizumab produced a 56% confirmed overall response rate (22/39) and a 10% complete response rate in PD-L1-positive, HPV-unrelated recurrent or metastatic HNSCC.
Median follow-up was 10.4 months; median PFS was 7.7 months and median OS was not estimable. Safety matched known profiles with no new signals.
Johnson & Johnson (NYSE: JNJ) announced a more than $1 billion investment in a next‑generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. The site is expected to create >4,000 construction jobs and >500 biomanufacturing jobs and is part of a $55 billion U.S. investment through early 2029.
This expands JNJ’s Pennsylvania footprint, supporting its roughly $10 billion annual economic impact and adding to ten statewide facilities totaling more than 2 million square feet.
Johnson & Johnson (NYSE: JNJ) announced that the U.S. FDA granted Breakthrough Therapy Designation on Feb 18, 2026 for subcutaneous RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) as monotherapy for adults with recurrent or metastatic, HPV-unrelated head and neck squamous cell carcinoma after platinum and PD-1/PD-L1 therapy.
The designation is based on Phase 1b/2 OrigAMI-4 data showing rapid, durable responses in a heavily pretreated population; a Phase 3 OrigAMI-5 trial is ongoing.
Johnson & Johnson (NYSE: JNJ) announced FDA approval of a new monthly dosing schedule for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combined with oral LAZCLUZE for first-line EGFR-mutated advanced NSCLC, available as early as Week 5.
The approval preserves established efficacy and safety versus the bi-weekly subcutaneous schedule, shows pharmacokinetic comparability to prior IV and SC regimens, and reports a fivefold reduction in administration-related reactions versus historical IV delivery.
Summary not available.
Johnson & Johnson (NYSE: JNJ) will present at the Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026, with management in a Fireside Chat at 11:30 a.m. ET. A live audio webcast and an archived replay (available ~48 hours later) will be on the company's investor website.
Johnson & Johnson (NYSE: JNJ) presented 12-month pilot-phase OMNY-AF results showing 90% freedom from atrial fibrillation and 100% acute procedural success across a 30-patient cohort, with no procedure-related adverse events and 56.7% of cases using zero fluoroscopy.
Presentations also highlighted VARIPULSE platform safety: a 0.22% neurovascular event rate in 6,811 patients after workflow and irrigation optimizations, and high same-day discharge rates.